EcoDrugPlus

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSCSEG00000001018
Gene Symbol: LOC103390423
3 Cross references
210 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSCSEG00000002863
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSCSEG00000014924
Gene Symbol: LOC103398737
3 Cross references
190 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSCSEG00000019575
Gene Symbol: CCR9
3 Cross references
194 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSCSEG00000013981
Gene Symbol: CXCR4
4 Cross references
216 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSCSEG00000001950
Gene Symbol: LOC103388208
2 Cross references
352 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSCSEG00000008535
Gene Symbol: LOC103388570
2 Cross references
415 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCSEG00000021346
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

D(4) Dopamine Receptor

Ensembl ID : ENSCSEG00000005908
Gene Symbol: LOC103378863
4 Cross references
175 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSCSEG00000021029
Gene Symbol: DNMT1
3 Cross references
212 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSCSEG00000009818
Gene Symbol: TOP1
3 Cross references
208 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSCSEG00000012668
Gene Symbol: TOP2A
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).